Aris Baras and Vivek Ramaswamy Make The List: Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine
Vice President, Regeneron Pharmaceuticals
Aris Baras is the child of immigrants from Greece
Fellowship awarded to support work towards an MD in Medicine at Duke University
ARIS BARAS serves as Executive Director and Co-Head of the Regeneron Genetics Center. Previously, he held roles and responsibilities at Regeneron in R&D Strategy and Business Development, as well as in Translational Medicine and Technology Development. Prior to Regeneron, Dr. Baras worked with Liquidia Technologies, a nanotechnology company developing vaccines and respiratory therapeutics, and the Wakefield Group, a venture capital firm in Research Triangle Park, NC. Dr. Baras received his Bachelor's Degree in Biology and Economics, his M.D., and M.B.A., all from Duke University. While at Duke University, Dr. Baras conducted biomedical research in the Cancer Center and Immunology Department studying mechanisms of action and resistance in B-cell depleting immunotherapies, as well as inflammatory breast cancer and mechanisms of resistance to ErbB2/HER2 targeting therapeutics. Aris was born in the United States to naturalized US citizen parents from Greece.